Ask about this productRelated genes to: CD80 antibody
- Gene:
- CD80 NIH gene
- Name:
- CD80 molecule
- Previous symbol:
- CD28LG, CD28LG1
- Synonyms:
- B7.1, B7-1
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-14
- Date modifiied:
- 2016-10-05
Related products to: CD80 antibody
Related articles to: CD80 antibody
- Adjuvants are critical for enhancing vaccine efficacy, however, conventional adjuvants often suffer from poor biocompatibility and limited immune activation profiles. Herein, we developed a nanoadjuvant by modifying a lentinan (LNT) backbone with polyethyleneimine (PEI) to generate a cationic LNT-PEI vector, which was then used to load SOCS1 siRNA, forming LNT-PEI/siRNA nanocomplexes. experiments demonstrated that LNT-PEI/siRNA effectively silenced gene expression, significantly upregulated the expression of CD80 and CD86, and promoted the secretion of TNF-α and IL-6. Furthermore, a vaccine was formulated by self-assembling the LNT-PEI/siRNA nanoadjuvant with the model antigen ovalbumin (OVA) to evaluate its immunostimulatory capacity. Biodistribution studies revealed that the vaccine formulation effectively targeted and accumulated in lymph nodes while reducing non-specific hepatic retention. Immunological evaluation showed that incorporation of LNT-PEI/siRNA markedly increased the proportions of CD11bF4/80 macrophages and CD11c dendritic cells, as well as CD3CD8a T cells in the spleen. It also upregulated costimulatory molecule expression and elevated serum levels of TNF-α, IL-6, and IFN-γ. In summary, the LNT-PEI/siRNA nanoadjuvant developed in this study successfully enhances immune responses, providing both a theoretical foundation and experimental basis for the development of next-generation vaccine adjuvants. - Source: PubMed
Publication date: 2026/08/14
Zhu YingShen YaoyanBao YumengMei CongjinZhou JuanChen Jinghua - Smoking cessation decreases lung cancer progression; however, its effects on precancerous lesions and the underlying mechanisms remain unclear. This study established a mouse model of precancerous pulmonary nodules and employed single-cell RNA sequencing (scRNA-seq) and immune repertoire sequencing (IR-seq) to elucidate the regulatory mechanisms by which smoking cessation influences the development of lung precancerous lesions. - Source: PubMed
Publication date: 2026/08/13
Wang XintongTang FangQin JiayuXiao TiquanShi LiweiZhang ShujunChe Chunli - Endometriosis (EMS) is a chronic inflammatory disorder involving ectopic endometrial tissue growth. This study investigated IL-33, CD1c+ dendritic cells (DCs) and their co-stimulatory molecules (CD40, CD80, CD86), and IL-17 A in the peritoneal fluid (PF) of EMS patients, and explored their interrelationships. - Source: PubMed
Publication date: 2026/08/13
Yuan WenHuang JiaoHe TaoLi HuanniWu Xianqing - Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape of advanced malignancies. However, only a subset of patients respond to treatment. Recent efforts have focused on the identification of novel biomarkers that capture the dynamic and functional state of the tumour immune microenvironment, yet their clinical translation has remained challenging. To address these limitations, we applied amplified FRET-FLIM (QF-Pro) technology to spatially resolve and quantitatively assess functional immune checkpoint interactions directly in cells and FFPE tissue and tumour samples. Using this approach, we demonstrated that PD-1/PD-L1, CTLA-4/CD80, TIGIT/CD155, and LAG-3/MHC-II interactions can be robustly quantified in routine FFPE patient samples from multiple tumour types. Furthermore, in a proof-of-concept study in a melanoma cohort treated with immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA-4, co-analysis of all four immune checkpoints suggested patterns of concomitant engagement. Notably, patients with high PD-1/PD-L1 interaction levels tended to also exhibit elevated CTLA-4/CD80 interactions. Survival analysis further showed that high LAG-3/MHC-II interaction status was associated with a trend toward improved overall survival even when corrected for tumour stage, irrespective of the specific ICI regimen administered. Although prospective validation in larger independent cohorts would be critical to establish clinical relevance, these findings support the exploration of LAG-3 engagement as a potential biomarker in melanoma immunotherapy, and more broadly highlight immune checkpoint interaction profiling as a promising avenue to examine in patient stratification. - Source: PubMed
Publication date: 2026/07/23
Cacho-Navas CristinaCamacho LauraAgüero JonBatmunkh BaterdeneGracia José Maríade Andrea Carlos EMartín-Algarra SalvadorRementeria MarkelMiles JamesGumuzio JuanAguirre FernandoParker Peter JCalleja Véronique - Tumor-associated macrophages are key components of the tumor microenvironment in oral carcinogenesis; however, their role is not yet fully understood. We aimed to characterize the expression of macrophage (M) markers across the spectrum of oral carcinogenesis, including oral leukoplakias (OL) and oral squamous cell carcinomas (OSCCs). This immunohistochemical study analyzed the macrophage density (cells/mm) based on the expression of CD68 (pan-macrophage), CD163 (M2), and CD80 (M1) in 81 samples, including healthy mucosa ( = 16), OL ( = 30), and OSCC ( = 35), in both epithelial and subepithelial compartments. All markers showed a progressive increase across the study groups, with significantly higher densities in OSCC than in healthy mucosa ( < 0.001), consistently higher in the subepithelial compartment. CD163 was the most expressed marker (increasing from 78.96 cells/mm in healthy mucosa to 300.56 cells/mm in OSCC), whereas CD80 was the least abundant, particularly in OSCC (35.66 cells/mm in healthy tissue to 188.49 cells/mm in OSCC). No significant associations were observed between biomarker expression and clinicopathological variables. These results support the involvement of macrophages during oral carcinogenesis, particularly CD163+ (M2) cells, and highlight the potential prognostic and therapeutic relevance of these markers. - Source: PubMed
Publication date: 2026/08/01
Alves MafaldaFerreira SaraGarcês FernandaEspíndula CarolinaSalazar FilomenaPacheco José JúlioDiniz-Freitas MárcioLopes CarlosWarnakulasuriya SamanDelgado LeonorMonteiro Luis